The effects of daily consumption of grapefruit on body weight, lipids, and blood pressure in healthy, overweight adults

Published:February 10, 2012DOI:


      Folklore has suggested that consuming grapefruit may promote weight control. Sparse data exist to support this hypothesis, although there is some evidence of health promotion effects with regard to blood pressure control and modulation of circulating lipids. The aim of this randomized controlled trial was to prospectively evaluate the role of grapefruit in reducing body weight and blood pressure and in promoting improvements in the lipid profile in overweight adults (N = 74). Following a 3-week washout diet low in bioactive-rich fruits and vegetables, participants were randomized to either the control diet (n = 32) or daily grapefruit (n = 42) in the amount of one half of a fresh Rio-Red grapefruit with each meal (3× daily) for 6 weeks. No differences between group in weight, blood pressure, or lipids were demonstrated. Grapefruit consumption was associated with modest weight loss (−0.61 ± 2.23 kg, P = .097), a significant reduction in waist circumference (−2.45 ± 0.60 cm, P = .0002), and a significant reduction in systolic blood pressure (−3.21 ± 10.13 mm Hg, P = .03) compared with baseline values. Improvements were observed in circulating lipids of those consuming grapefruit, with total cholesterol and low-density lipoprotein significantly decreasing by −11.7 mg/dL (P = .002) and −18.7 mg/dL (P < .001), respectively, compared with baseline values. This study suggests that consumption of grapefruit daily for 6 weeks does not significantly decrease body weight, lipids, or blood pressure as compared with the control condition. However, the improvements in blood pressure and lipids demonstrated in the intervention group suggest that grapefruit should be further evaluated in the context of obesity and cardiovascular disease prevention.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Metabolism - Clinical and Experimental
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ghandehari H.
        • Le V.
        • Kamal-Bahl S.
        • et al.
        Abdominal obesity and the spectrum of global cardiometabolic risks in US adults.
        Int J Obes (Lond). 2009; 33: 239-248
      1. Russell GV, Pierce CW, Nunley. L. Financial implications of obesity. Orthop Clin North Am 2011, 42:123-7, vii.

        • Selassie M.
        • Sinha A.C.
        The epidemiology and aetiology of obesity: a global challenge.
        Best Pract Res Clin Anaesthesiol. 2011; 25: 1-9
        • Bakris G.L.
        Current perspectives on hypertension and metabolic syndrome.
        J Manag Care Pharm. 2007; 13: S3-5
        • Heidenreich P.A.
        • Trogdon J.G.
        • Khavjou O.A.
        • et al.
        Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association.
        Circulation. 2011; 123: 933-944
      2. Zelman K. The grapefruit diet: what it is. Healthy eating diet. Accessed at on May 27, 2011.

        • Duyff R.L.
        Food folklore: tales and truths about what we eat. 1st ed. pp 23.
        John Wiley & Sons, New York, NY1999
        • Dallas C.
        • Gerbi A.
        • Tenca G.
        • et al.
        Lipolytic effect of a polyphenolic citrus dry extract of red orange, grapefruit, orange (SINETROL) in human body fat adipocytes. Mechanism of action by inhibition of cAMP-phosphodiesterase (PDE).
        Phytomedicine. 2008; 15: 783-792
        • Cho K.W.
        • Kim Y.O.
        • Andrade J.E.
        • et al.
        Dietary naringenin increases hepatic peroxisome proliferators-activated receptor alpha protein expression and decreases plasma triglyceride and adiposity in rats.
        Eur J Nutr. 2011; 50: 81-88
        • Silver H.J.
        • Dietrich M.S.
        • Niswender K.D.
        Effects of grapefruit, grapefruit juice and water preloads on energy balance, weight loss, body composition, and cardiometabolic risk in free-living obese adults.
        Nutr Metab (Lond). 2011; 8: 8
        • Fujioka K.
        • Greenway F.
        • Sheard J.
        • et al.
        The effects of grapefruit on weight and insulin resistance: relationship to the metabolic syndrome.
        J Med Food. 2006; 9: 49-54
        • Flood-Obbagy J.E.
        • Rolls B.J.
        The effect of fruit in different forms on energy intake and satiety at a meal.
        Appetite. 2009; 52: 416-422
        • Erlund I.
        • Silaste M.L.
        • Alfthan G.
        • et al.
        Plasma concentrations of the flavonoids hesperetin, naringenin and quercetin in human subjects following their habitual diets, and diets high or low in fruit and vegetables.
        Eur J Clin Nutr. 2002; 56: 891-898
        • Rizza S.
        • Muniyappa R.
        • Iantorno M.
        • et al.
        Citrus polyphenol hesperidin stimulates production of nitric oxide in endothelial cells while improving endothelial function and reducing inflammatory markers in patients with metabolic syndrome.
        J Clin Endocrinol Metab. 2011; 96: E782-792
        • Morand C.
        • Dubray C.
        • Milenkovic D.
        • et al.
        Hesperidin contributes to the vascular protective effects of orange juice: a randomized crossover study in healthy volunteers.
        Am J Clin Nutr. 2011; 93: 73-80
        • Demonty I.
        • Lin Y.
        • Zebregs Y.E.
        • et al.
        The citrus flavonoids hesperidin and naringin do not affect serum cholesterol in moderately hypercholesterolemic men and women.
        J Nutr. 2010; 140: 1615-1620
        • Orallo F.
        • Camina M.
        • Alvarez E.
        • et al.
        Implication of cyclic nucleotide phosphodiesterase inhibition in the vasorelaxant activity of the citrus-fruits flavonoid (+/−)-naringenin.
        Planta Med. 2005; 71: 99-107
        • Kim S.Y.
        • Kim H.J.
        • Lee M.K.
        • et al.
        Naringin time-dependently lowers hepatic cholesterol biosynthesis and plasma cholesterol in rats fed high-fat and high-cholesterol diet.
        J Med Food. 2006; 9: 582-586
        • Mulvihill E.E.
        • Allister E.M.
        • Sutherland B.G.
        • et al.
        Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDL receptor–null mice with diet-induced insulin resistance.
        Diabetes. 2009; 58: 2198-2210
        • Jeon S.M.
        • Kim H.K.
        • Kim H.J.
        • et al.
        Hypocholesterolemic and antioxidative effects of naringenin and its two metabolites in high-cholesterol fed rats.
        Transl Res. 2007; 149: 15-21
        • Gupta R.
        • Guptha S.
        Strategies for initial management of hypertension.
        Indian J Med Res. 2010; 132: 531-542
        • Gorinstein S.
        • Caspi A.
        • Libman I.
        • et al.
        Red grapefruit positively influences serum triglyceride level in patients suffering from coronary atherosclerosis: studies in vitro and in humans.
        J Agric Food Chem. 2006; 54: 1887-1892
        • Landberg R.
        • Sun Q.
        • Rimm E.B.
        • et al.
        Selected dietary flavonoids are associated with markers of inflammation and endothelial dysfunction in U.S. women.
        J Nutr. 2011; 141: 618-625
        • Raper N.P.B.
        • Ingwersen L.
        • Steinfeldt L.
        • Anand J.
        An overview of USDA's Dietary Intake Data System.
        J Food Compos Anal. 2004; 17: 545-555
        • Lohman T.G.
        • Roche A.F.
        • Martorell R.
        Anthropometric standardization reference manual.
        Human Kinetics Books, Champaign (Ill)1988
        • Dale R.A.
        • Jensen L.H.
        • Krantz M.J.
        Comparison of two point-of-care lipid analyzers for use in global cardiovascular risk assessments.
        Ann Pharmacother. 2008; 42: 633-639
        • Girennavar B.J.G.
        • Jifon J.L.
        • Patil B.S.
        Variation of bioactive furocoumarins and flavonoids in different varieties of grapefruit and pummelo.
        Eur Food Res Technol. 2008; 226: 1269-1275
        • Freedman L.S.
        • Schatzkin A.
        • Midthune D.
        • et al.
        Dealing with dietary measurement error in nutritional cohort studies.
        J Natl Cancer Inst. 2011; 103: 1086-1092
        • Shen W.
        • Punyanitya M.
        • Chen J.
        • et al.
        Waist circumference correlates with metabolic syndrome indicators better than percentage fat.
        Obesity (Silver Spring). 2006; 14: 727-736
        • Giles T.D.
        • Berk B.C.
        • Black H.R.
        • et al.
        Expanding the definition and classification of hypertension.
        J Clin Hypertens (Greenwich). 2005; 7: 505-512
        • Wilburn A.J.
        • King D.S.
        • Glisson J.
        • et al.
        The natural treatment of hypertension.
        J Clin Hypertens (Greenwich). 2004; 6: 242-248
        • Antoniades C.
        • Shirodaria C.
        • Warrick N.
        • et al.
        5-Methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling.
        Circulation. 2006; 114: 1193-1201
        • Jung U.J.
        • Kim H.J.
        • Lee J.S.
        • et al.
        Naringin supplementation lowers plasma lipids and enhances erythrocyte antioxidant enzyme activities in hypercholesterolemic subjects.
        Clin Nutr. 2003; 22: 561-568
        • Anderson J.W.
        • Baird P.
        • Davis Jr, R.H.
        • et al.
        Health benefits of dietary fiber.
        Nutr Rev. 2009; 67: 188-205
        • Lopez-Jimenez F.
        • Cortes-Bergoderi M.
        Update: systemic diseases and the cardiovascular system (i): obesity and the heart.
        Rev Esp Cardiol. 2011; 64: 140-149
        • Lardizabal J.A.
        • Deedwania P.C.
        Benefits of statin therapy and compliance in high risk cardiovascular patients.
        Vasc Health Risk Manag. 2010; 6: 843-853
        • Mukhtar R.Y.
        • Reckless J.P.
        Statin-induced myositis: a commonly encountered or rare side effect?.
        Curr Opin Lipidol. 2005; 16: 640-647
        • Fichtlscherer S.
        • Schmidt-Lucke C.
        • Bojunga S.
        • et al.
        Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for 'pleiotropic' functions of statin therapy.
        Eur Heart J. 2006; 27: 1182-1190
        • Dhaliwal S.S.
        • Welborn T.A.
        Measurement error and ethnic comparisons of measures of abdominal obesity.
        Prev Med. 2009; 49: 148-152